Loading…
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affe...
Saved in:
Published in: | Dialogues in clinical neuroscience 2014-12, Vol.16 (4), p.505-524 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3 |
container_end_page | 524 |
container_issue | 4 |
container_start_page | 505 |
container_title | Dialogues in clinical neuroscience |
container_volume | 16 |
creator | Carbon, Maren Correll, Christoph U. |
description | The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available. |
doi_str_mv | 10.31887/DCNS.2014.16.4/mcarbon |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25733955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1660655813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</originalsourceid><addsrcrecordid>eNqFUc9P2zAUtqahwdj-Bchxl7Z2EjvxBWkrbExCcICdLeflhRgldrBdUPfXz6ylKicutqXv13v-CDlldF6wuq4W58vr23lOWTlnYl4uRtC-cfYDOWKS1zMuhfy49z4kn0N4oJSLJPlEDnNeFYXk_IhcLwdjDeghmzy2BqLzIXNdFnv0esJVNJB5DJOzAbPoMm2jmcIaepeQkBmbBejNXzf1Hq3RX8hBp4eAX7f3Mfnz8-JueTm7uvn1e_n9agaCsjhrRQOypiUw3tCqrrBNS7F0yIpTqOuixQa7jomW5aBZo1FUnaa5RGBtLqE4Jmcb32nVjNgC2uj1oCZvRu3Xymmj3iLW9OrePamyKITMaTL4tjXw7nGFIarRBMBh0BbdKigmBBWc16xI1GpDBe9C8NjtYhhV_9tQL22olzaSTpVq20ZSnuxPudO9fn8i_NgQjO2cH_Wz80Orol4PzndeWzAhJbyT8g9LaaMw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1660655813</pqid></control><display><type>article</type><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><source>PubMed (Medline)</source><source>Taylor & Francis (Open access)</source><creator>Carbon, Maren ; Correll, Christoph U.</creator><creatorcontrib>Carbon, Maren ; Correll, Christoph U.</creatorcontrib><description>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</description><identifier>ISSN: 1958-5969</identifier><identifier>ISSN: 1294-8322</identifier><identifier>EISSN: 1958-5969</identifier><identifier>DOI: 10.31887/DCNS.2014.16.4/mcarbon</identifier><identifier>PMID: 25733955</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Antipsychotic Agents - therapeutic use ; association ; Clinical Research ; Humans ; marker ; predictor ; psychosis ; remission ; response ; Risk Factors ; schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology</subject><ispartof>Dialogues in clinical neuroscience, 2014-12, Vol.16 (4), p.505-524</ispartof><rights>Copyright: © 2014 Institut la Conférence Hippocrate - Servier Research Group 2014</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</citedby><cites>FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336920/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336920/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27502,27924,27925,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25733955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carbon, Maren</creatorcontrib><creatorcontrib>Correll, Christoph U.</creatorcontrib><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><title>Dialogues in clinical neuroscience</title><addtitle>Dialogues Clin Neurosci</addtitle><description>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</description><subject>Antipsychotic Agents - therapeutic use</subject><subject>association</subject><subject>Clinical Research</subject><subject>Humans</subject><subject>marker</subject><subject>predictor</subject><subject>psychosis</subject><subject>remission</subject><subject>response</subject><subject>Risk Factors</subject><subject>schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><issn>1958-5969</issn><issn>1294-8322</issn><issn>1958-5969</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNqFUc9P2zAUtqahwdj-Bchxl7Z2EjvxBWkrbExCcICdLeflhRgldrBdUPfXz6ylKicutqXv13v-CDlldF6wuq4W58vr23lOWTlnYl4uRtC-cfYDOWKS1zMuhfy49z4kn0N4oJSLJPlEDnNeFYXk_IhcLwdjDeghmzy2BqLzIXNdFnv0esJVNJB5DJOzAbPoMm2jmcIaepeQkBmbBejNXzf1Hq3RX8hBp4eAX7f3Mfnz8-JueTm7uvn1e_n9agaCsjhrRQOypiUw3tCqrrBNS7F0yIpTqOuixQa7jomW5aBZo1FUnaa5RGBtLqE4Jmcb32nVjNgC2uj1oCZvRu3Xymmj3iLW9OrePamyKITMaTL4tjXw7nGFIarRBMBh0BbdKigmBBWc16xI1GpDBe9C8NjtYhhV_9tQL22olzaSTpVq20ZSnuxPudO9fn8i_NgQjO2cH_Wz80Orol4PzndeWzAhJbyT8g9LaaMw</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Carbon, Maren</creator><creator>Correll, Christoph U.</creator><general>Taylor & Francis</general><general>Les Laboratoires Servier</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20141201</creationdate><title>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</title><author>Carbon, Maren ; Correll, Christoph U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antipsychotic Agents - therapeutic use</topic><topic>association</topic><topic>Clinical Research</topic><topic>Humans</topic><topic>marker</topic><topic>predictor</topic><topic>psychosis</topic><topic>remission</topic><topic>response</topic><topic>Risk Factors</topic><topic>schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><toplevel>online_resources</toplevel><creatorcontrib>Carbon, Maren</creatorcontrib><creatorcontrib>Correll, Christoph U.</creatorcontrib><collection>Taylor & Francis (Open access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Dialogues in clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carbon, Maren</au><au>Correll, Christoph U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical predictors of therapeutic response to antipsychotics in schizophrenia</atitle><jtitle>Dialogues in clinical neuroscience</jtitle><addtitle>Dialogues Clin Neurosci</addtitle><date>2014-12-01</date><risdate>2014</risdate><volume>16</volume><issue>4</issue><spage>505</spage><epage>524</epage><pages>505-524</pages><issn>1958-5969</issn><issn>1294-8322</issn><eissn>1958-5969</eissn><abstract>The search for clinical outcome predictors for schizophrenia is as old as the field of psychiatry. However, despite a wealth of large, longitudinal studies into prognostic factors, only very few clinically useful outcome predictors have been identified. The goal of future treatment is to either affect modifiable risk factors, or use nonmodifiable factors to parse patients into therapeutically meaningful subgroups. Most clinical outcome predictors are nonspecific and/or nonmodifiable. Nonmodifiable predictors for poor odds of remission include male sex, younger age at disease onset, poor premorbid adjustment, and severe baseline psychopathology. Modifiable risk factors for poor therapeutic outcomes that clinicians can act upon include longer duration of untreated illness, nonadherence to antipsychotics, comorbidities (especially substance-use disorders), lack of early antipsychotic response, and lack of improvement with non-clozapine antipsychotics, predicting clozapine response. It is hoped that this limited capacity for prediction will improve as pathophysiological understanding increases and/or new treatments for specific aspects of schizophrenia become available.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>25733955</pmid><doi>10.31887/DCNS.2014.16.4/mcarbon</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1958-5969 |
ispartof | Dialogues in clinical neuroscience, 2014-12, Vol.16 (4), p.505-524 |
issn | 1958-5969 1294-8322 1958-5969 |
language | eng |
recordid | cdi_pubmed_primary_25733955 |
source | PubMed (Medline); Taylor & Francis (Open access) |
subjects | Antipsychotic Agents - therapeutic use association Clinical Research Humans marker predictor psychosis remission response Risk Factors schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology |
title | Clinical predictors of therapeutic response to antipsychotics in schizophrenia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A43%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20predictors%20of%20therapeutic%20response%20to%20antipsychotics%20in%20schizophrenia&rft.jtitle=Dialogues%20in%20clinical%20neuroscience&rft.au=Carbon,%20Maren&rft.date=2014-12-01&rft.volume=16&rft.issue=4&rft.spage=505&rft.epage=524&rft.pages=505-524&rft.issn=1958-5969&rft.eissn=1958-5969&rft_id=info:doi/10.31887/DCNS.2014.16.4/mcarbon&rft_dat=%3Cproquest_pubme%3E1660655813%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c601t-d6bc9804c15b0787ed1881d189750c883debeff16d12ca1bae67fa029ec1d29c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1660655813&rft_id=info:pmid/25733955&rfr_iscdi=true |